Advertisement

Aveo Oncology (Nasdaq: AVEO) of Cambridge and Astellas Pharma Inc. (TSE: 4503) of Tokyo  said they plan to start a new clinical trial in advanced renal cell carcinoma to establish more data for their investigational drug tivozanib when used as a first-line therapy in those cancer patients.

The study is designed to build upon safety profile demonstrated in TIVO-1 study, according to a statement from the companies. In February 2011, Aveo and Astellas entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib to treat a broad range of cancers.

SOURCE

Advertisement
Advertisement